Technical analysis of Petros Pharmaceuticals, Inc. (PTPI): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Petros Pharmaceuticals, Inc. is a pharmaceutical company dedicated to male health solutions. Their activities include both the commercialization and ongoing development of Stendra, a prescription PDE-5 inhibitor specifically designed for treating erectile dysfunction (ED). Furthermore, Petros is advancing H100, a proprietary topical formulation currently in development as a potential treatment for acute Peyronie's disease.
Price Performance
| 1 month | +96.43% |
| 3 months | -9.02% |
| Year-to-date | -31.25% |
| 1 year | -78.85% |
| 3 years | -99.99% |
| 5 years | -100.00% |
52-Week Range
| 52-week High | $0.03 |
| 52-week Low | $0.00 |
| Avg Volume (90d) | 110K |
Technical Indicators
| SMA 50 | $0.00 |
| SMA 200 | $0.01 |
| 30-day Volatility (annualised) | 228.2% |
| Price vs SMA 50 | +30.0% |
| Price vs SMA 200 | -18.0% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $0.02 | |
| 2025-11 | $0.01 | -36.8% |
| 2025-12 | $0.01 | -33.3% |
| 2026-01 | $0.01 | +0.0% |
| 2026-02 | $0.01 | -12.5% |
| 2026-03 | $0.01 | -14.3% |
| 2026-04 | $0.01 | +16.7% |
| 2026-05 | $0.01 | -14.3% |
| 2026-06 | $0.01 | -15.0% |
| 2026-07 | $0.00 | -41.2% |
| 2026-08 | $0.00 | +20.0% |
| 2026-09 | $0.01 | +52.8% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | | |
| 2026-09-14 | | $563M |
| 2026-09-14 | | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $0.20 | $23M |
| 2026-09-14 | | |
Price
| Price | $0.01 |
| Market Cap | $0M |
| Exchange | OTC |
| Country | US |
Valuation Ratios
| P/E Ratio | 0.00 |
| Price / Book | 0.33 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 1.25 |